MSLE News and Press, Satellos Bioscience Inc.

SAT-3247 has now received FDA Fast Track, Orphan Drug and Rare Pediatric Disease designations for Duchenne muscular dystrophy (“Duchenne” or “DMD”) Fast Track is designed to expedite the development/review of new drugs to treat serious or life-threatening conditions...

TORONTO, June 25, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL)  (“ Satellos ” or the “ Company ”), a clinical-stage biotechnology company developing novel therapies to treat degenerative muscle diseases, today announced that new dat...

TORONTO, June 17, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL)  (“ Satellos ” or the “ Company ”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, announced today the...

2026-05-15 09:17:23 ET More on Satellos Bioscience Inc. Historical earnings data for Satellos Bioscience Inc. Financial information for Satellos Bioscience Inc. Read the full article on Seeking Alpha For further details see: Satellos Bioscience GAAP EPS o...

Eleven clinical trial sites in BASECAMP currently active; remaining planned sites to be activated throughout Q2 2026 BASECAMP remains on track to complete enrollment in Q3 2026 The Company has initiated the TRAILHEAD study in the U.S. in adults aged 16-25 years. Current cash available of...

TORONTO, April 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL)  (“  Satellos  ” or the “  Company  ”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle dise...

2026-03-27 07:06:59 ET More on Satellos Bioscience Inc. Satellos prices $50M public offering Satellos launches public offering, applies for Nasdaq listing Historical earnings data for Satellos Bioscience Inc. Financial information for Satellos Bioscience Inc....

Completed a US$57.2 million equity financing; commenced trading on the Nasdaq Global Market under the ticker “MSLE” on Feb. 6, 2026 Secured global regulatory clearances and initiated BASECAMP, a placebo-controlled Phase 2 clinical trial of SAT-3247 in boys aged 7 to less than ...

A look at the top 10 most actives in the United States Decent Holding Inc. (DXST) rose 50.4% to $0.3986 on volume of 392,509,512 shares Elong Power Holding Limited (ELPW) fell 98.3% to $0.0637 on volume of 345,469,270 shares Longeveron Inc. (LGVN) rose 68.3% to $0.891 on volume of 248,906,9...

Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements Greater improvements in strength observed in participants with greater baseline muscle mass, further supporti...